Biotech | August 25, 2025
Boehringer and AnGes sign manufacturing agreement for HGF gene therapy product
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Norepinephrine Bitartratein 5% Dextrose of Baxter Healthcare Corp
AINU is set to accelerate its expansion footprint, enhance operational capabilities
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
The submission is supported by results from the Phase 3b APEX study
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The company has projected Rs. 5,630 crores of investment and to provide employment to 6,350 people in three phases over a period of eight years
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Subscribe To Our Newsletter & Stay Updated
